Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer

INTRODUCTION: Alterations in the MET gene, including amplifications and exon 14 skipping mutations, have been identified as actionable oncogenic alterations. However, MET fusions are rarely detected in lung cancer, and their sensitivity to therapeutics has not been systematically analyzed. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Dantong, Wu, Weizheng, Wang, Li, Qu, Jialin, Han, Qiman, Wang, Huiyun, Song, Shanai, Liu, Ning, Wang, Yongjie, Hou, Helei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960416/
https://www.ncbi.nlm.nih.gov/pubmed/36829199
http://dx.doi.org/10.1186/s12967-023-03999-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960416/
https://www.ncbi.nlm.nih.gov/pubmed/36829199
http://dx.doi.org/10.1186/s12967-023-03999-7

Ejemplares similares